Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations

Hepatology

Volumn 56, Issue 3, 2012, Pages 793-796

  Sherman, Morris ^a   Bruix, Jordi ^b   Porayko, Michael ^c   Tran, Tram ^d  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b HOSPITAL CLÍNIC   (Spain)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CHINA; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ERROR; EARLY DIAGNOSIS; ECHOGRAPHY; EDITORIAL; EVIDENCE BASED MEDICINE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; NORTH AMERICA; PATIENT PARTICIPATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAMPLE SIZE; STUDY DESIGN; SYSTEMATIC ERROR; TUMOR ABLATION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84865538893     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25869     Document Type: Editorial

References (36)

1. Lederle F, Pota C. Screening for hepatocellular carcinoma: a rush to judgment. Ann Int Med 2012; 156: 387-389.
2. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208-1236.
3. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
4. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
5. Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802-1829.
6. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al.; World Gastroenterology Organisation Guidelines and Publications Committee. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010; 19: 311-317.
7. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL EORTC Practice Management Guidelines: hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
8. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical Practice Guidelines Proposed by the Japan Society of Hepatology 2010 updated version. Dig Dis Sci 2011; 29: 339-364.
9. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
10. Benson AB, 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, et al. NCCN Clinical Practice Guidelines in Oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-391.
11. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204-209.
12. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC, Jr. Scientific evidence underlying the ACC/AHA Clinical Practice Guidelines. JAMA 2009; 301: 831-841.
13. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008; 6: 1418-1424.
14. Shih ST, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc 2010; 109: 39-55.
15. Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003; 9: 672-681.
16. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101: 422-434.
17. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11: 1-206.
18. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98: 679-690.
19. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 75-84.
20. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19: 1159-1172.
21. Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 2008; 23: 437-444.
22. Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008; 121: 119-126.
23. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnù L, Zoli M, et al.; Italian Liver Cancer Group. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-744.
24. Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, et al.; Italian Liver Cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004; 99: 1470-1476.
25. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al.; Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291-297.
26. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010; 46: 744-751.
27. Huo TI, Huang YH, Chiang JH, Wu JC, Lee PC, Chi CW, Lee SD. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias? Scand J Gastroenterol 2007; 42: 485-492.
28. Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010; 55: 826-835.
29. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? HEPATOLOGY 2011; 54: 1998-2004.
30. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? HEPATOLOGY 2008; 47: 82-89.
31. Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguri M, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 2000; 191: 381-388.
32. Yeh CN, Lee WC, Chen MF, Tsay PK. Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol 2003; 10: 916-921.
33. Sandhu L, Sandroussi C, Guba M, Selzner M, Ghanekar A, Cattral MS, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 2012; 18: 315-322.
34. Ho CM, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann Surg Oncol 2012; 19: 826-833.
35. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
36. Dryden K. Ken Dryden takes a close look at three hits through the ages. The Globe and Mail, Toronto, April 27, 2012.